Cargando…

Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications

Cancer is one of the most frequently diagnosed malignant diseases worldwide, posing a serious, long-term threat to patients’ health and life. Systemic chemotherapy remains the first-line therapeutic approach for recurrent or metastatic cancer patients after surgery, with the potential to effectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xuehao, Ao, Xiang, Jia, Zhaojun, Li, Yiwen, Kuang, Shouxiang, Du, Chengcheng, Zhang, Jinyu, Wang, Jianxun, Liu, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428469/
https://www.ncbi.nlm.nih.gov/pubmed/36059609
http://dx.doi.org/10.3389/fonc.2022.951864
_version_ 1784779125923250176
author Zhou, Xuehao
Ao, Xiang
Jia, Zhaojun
Li, Yiwen
Kuang, Shouxiang
Du, Chengcheng
Zhang, Jinyu
Wang, Jianxun
Liu, Ying
author_facet Zhou, Xuehao
Ao, Xiang
Jia, Zhaojun
Li, Yiwen
Kuang, Shouxiang
Du, Chengcheng
Zhang, Jinyu
Wang, Jianxun
Liu, Ying
author_sort Zhou, Xuehao
collection PubMed
description Cancer is one of the most frequently diagnosed malignant diseases worldwide, posing a serious, long-term threat to patients’ health and life. Systemic chemotherapy remains the first-line therapeutic approach for recurrent or metastatic cancer patients after surgery, with the potential to effectively extend patient survival. However, the development of drug resistance seriously limits the clinical efficiency of chemotherapy and ultimately results in treatment failure and patient death. A large number of studies have shown that non-coding RNAs (ncRNAs), particularly microRNAs, long non-coding RNAs, and circular RNAs, are widely involved in the regulation of cancer drug resistance. Their dysregulation contributes to the development of cancer drug resistance by modulating the expression of specific target genes involved in cellular apoptosis, autophagy, drug efflux, epithelial-to-mesenchymal transition (EMT), and cancer stem cells (CSCs). Moreover, some ncRNAs also possess great potential as efficient, specific biomarkers in diagnosis and prognosis as well as therapeutic targets in cancer patients. In this review, we summarize the recent findings on the emerging role and underlying mechanisms of ncRNAs involved in cancer drug resistance and focus on their clinical applications as biomarkers and therapeutic targets in cancer treatment. This information will be of great benefit to early diagnosis and prognostic assessments of cancer as well as the development of ncRNA-based therapeutic strategies for cancer patients.
format Online
Article
Text
id pubmed-9428469
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94284692022-09-01 Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications Zhou, Xuehao Ao, Xiang Jia, Zhaojun Li, Yiwen Kuang, Shouxiang Du, Chengcheng Zhang, Jinyu Wang, Jianxun Liu, Ying Front Oncol Oncology Cancer is one of the most frequently diagnosed malignant diseases worldwide, posing a serious, long-term threat to patients’ health and life. Systemic chemotherapy remains the first-line therapeutic approach for recurrent or metastatic cancer patients after surgery, with the potential to effectively extend patient survival. However, the development of drug resistance seriously limits the clinical efficiency of chemotherapy and ultimately results in treatment failure and patient death. A large number of studies have shown that non-coding RNAs (ncRNAs), particularly microRNAs, long non-coding RNAs, and circular RNAs, are widely involved in the regulation of cancer drug resistance. Their dysregulation contributes to the development of cancer drug resistance by modulating the expression of specific target genes involved in cellular apoptosis, autophagy, drug efflux, epithelial-to-mesenchymal transition (EMT), and cancer stem cells (CSCs). Moreover, some ncRNAs also possess great potential as efficient, specific biomarkers in diagnosis and prognosis as well as therapeutic targets in cancer patients. In this review, we summarize the recent findings on the emerging role and underlying mechanisms of ncRNAs involved in cancer drug resistance and focus on their clinical applications as biomarkers and therapeutic targets in cancer treatment. This information will be of great benefit to early diagnosis and prognostic assessments of cancer as well as the development of ncRNA-based therapeutic strategies for cancer patients. Frontiers Media S.A. 2022-08-17 /pmc/articles/PMC9428469/ /pubmed/36059609 http://dx.doi.org/10.3389/fonc.2022.951864 Text en Copyright © 2022 Zhou, Ao, Jia, Li, Kuang, Du, Zhang, Wang and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhou, Xuehao
Ao, Xiang
Jia, Zhaojun
Li, Yiwen
Kuang, Shouxiang
Du, Chengcheng
Zhang, Jinyu
Wang, Jianxun
Liu, Ying
Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications
title Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications
title_full Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications
title_fullStr Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications
title_full_unstemmed Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications
title_short Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications
title_sort non-coding rna in cancer drug resistance: underlying mechanisms and clinical applications
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428469/
https://www.ncbi.nlm.nih.gov/pubmed/36059609
http://dx.doi.org/10.3389/fonc.2022.951864
work_keys_str_mv AT zhouxuehao noncodingrnaincancerdrugresistanceunderlyingmechanismsandclinicalapplications
AT aoxiang noncodingrnaincancerdrugresistanceunderlyingmechanismsandclinicalapplications
AT jiazhaojun noncodingrnaincancerdrugresistanceunderlyingmechanismsandclinicalapplications
AT liyiwen noncodingrnaincancerdrugresistanceunderlyingmechanismsandclinicalapplications
AT kuangshouxiang noncodingrnaincancerdrugresistanceunderlyingmechanismsandclinicalapplications
AT duchengcheng noncodingrnaincancerdrugresistanceunderlyingmechanismsandclinicalapplications
AT zhangjinyu noncodingrnaincancerdrugresistanceunderlyingmechanismsandclinicalapplications
AT wangjianxun noncodingrnaincancerdrugresistanceunderlyingmechanismsandclinicalapplications
AT liuying noncodingrnaincancerdrugresistanceunderlyingmechanismsandclinicalapplications